- There is an increased risk of incident mild cognitive impairment (MCI) and decline in cognitively normal (CN) older adults on anticholinergic medications (aCH); these effects are significantly increased in individuals with genetic risk factors and cerebrospinal fluid (CSF)-based Alzheimer’s disease (AD) pathophysiologic markers.
Why this matters
- Animal studies have demonstrated that cholinergic deprivation encourages plaque and tangle formation, neurodegeneration and accelerated decline in learning and memory.
- Identifying modifiable risk factors for AD is increasingly important as there is a paucity of reliable treatments; as such, reducing or substituting aCH medications in older adults with genetic and CSF markers or risk factors may positively impact the growing prevalence of AD.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.